DocGo Inc. (NASDAQ:DCGO) Given Average Rating of "Hold" by Brokerages
DocGo Inc. (NASDAQ:DCGO) has received an average "Hold" rating from seven brokerage firms, with an average 12-month price target of $2.375. The company's shares are currently trading around $0.57, below its 50-day and 200-day moving averages. Institutional investors and hedge funds own approximately 56.44% of the company, with several firms recently initiating or increasing their positions.
DocGo Inc. (DCGO) Stock Price | Live Quotes & Charts | NASDAQ
This page provides live quotes and charts for DocGo Inc. (DCGO) stock, showing its current price as $0.5752 with a 0.91% increase. It includes information on analyst ratings (currently none available) and advises that earnings information is not yet provided. The page also features promotional content for trading conferences and platforms.
DocGo (DCGO) CEO Bienstock has 18,811 shares withheld to cover RSU taxes
DocGo Inc.'s CEO, Lee Bienstock, had 18,811 shares of common stock withheld to cover tax liabilities associated with previously granted restricted stock units (RSUs). These shares were valued at $0.57 each and were withheld rather than sold on the open market. Following this transaction, Bienstock directly holds 2,817,470 shares of DocGo Common Stock.
DocGo (DCGO) price target decreased by 12.00% to 2.24
This article reports that the price target for DocGo (DCGO) has been decreased by 12.00%, bringing it down to $2.24. No further details regarding the reasons for this change or the issuing analyst are provided.
[SCHEDULE 13G/A] DocGo Inc. Amended Passive Investment Disclosure
The Vanguard Group filed an amended Schedule 13G/A for DocGo Inc., reporting 0% beneficial ownership due to an internal realignment effective January 12, 2026. This administrative filing clarifies reporting responsibilities among Vanguard entities, indicating that what appears to be a disposition is actually a disaggregation of reporting, and affirms no single outside holder owns more than 5%. Subsequent filings from Vanguard's separate entities may show where these holdings are now reported.
DocGo (NASDAQ:DCGO) Given New $1.00 Price Target at Canaccord Genuity Group
Canaccord Genuity Group has lowered its price target for DocGo (NASDAQ:DCGO) from $1.50 to $1.00, maintaining a "hold" rating, despite other firms holding higher targets. DocGo's stock is currently trading around $0.63 with a market capitalization of $62.21 million, and institutional investors own a significant portion of the company. The company, an integrated healthcare provider offering on-demand mobile services, has seen mixed analyst ratings with an average price target of $2.38.
Canaccord cuts DocGo stock price target on profitability concerns
Canaccord has lowered its price target for DocGo (NASDAQ:DCGO) to $1.00 from $1.50, citing concerns over profitability despite exceeding revenue estimates in Q4 2025. The company's adjusted EBITDA came in below estimates, though core transportation and mobile health volumes were strong, prompting raised 2026 guidance. DocGo aims for adjusted EBITDA profitability in the second half of 2026, and analysts suggest the stock may be undervalued with recovery potential.
Ethisphere Names DocGo as One of the 2026 World's Most Ethical Companies®
DocGo Inc. has been recognized by Ethisphere as one of the 2026 World's Most Ethical Companies®, marking its first time receiving this honor. The company is one of only four healthcare providers and services companies to be recognized, highlighting its commitment to ethical business practices and strong governance. DocGo's CEO, Lee Bienstock, emphasized that trust is at the core of their operations, influencing everything from patient care to data security.
Healthcare provider DocGo joins 2026 World's Most Ethical Companies list
DocGo (Nasdaq: DCGO), a provider of medical transportation and mobile health services, has been named one of the 2026 World's Most Ethical Companies by Ethisphere. This marks DocGo's first time receiving this honor, recognizing its commitment to business integrity through robust ethics, compliance, and governance programs. DocGo is one of only four honorees in the healthcare providers and services category, which CEO Lee Bienstock attributes to prioritizing trust, strong governance, accountability, and a culture of integrity.
DocGo (NASDAQ:DCGO) Announces Quarterly Earnings Results
DocGo (NASDAQ:DCGO) reported a significant earnings miss, with an EPS of ($1.37) against a consensus of ($0.09) but exceeded revenue expectations at $74.94 million. The company remains unprofitable, reflected in a negative net margin and return on equity. Following the announcement, shares traded down, and while analysts have a "Hold" consensus, Weiss Ratings reiterated a "Sell" opinion.
DocGo Inc. (NASDAQ:DCGO) Q4 2025 earnings call transcript
This is the Q4 2025 earnings call transcript for DocGo Inc. (NASDAQ:DCGO). The transcript covers the company's financial performance, operational highlights, and future outlook as discussed by management during the call.
DocGo Earnings Call Signals Turnaround Amid Cash Strain
DocGo's Q4 earnings call highlighted cautiously optimistic financial performance, with Q4 revenue topping guidance and an upgraded 2026 revenue outlook despite a significant year-over-year revenue drop due to exiting migrant contracts. The company narrowed its expected 2026 adjusted EBITDA loss and is integrating SteadyMD while focusing on efficiency initiatives. However, investors remain concerned about ongoing adjusted EBITDA losses, heavy non-cash impairments, and near-term liquidity strain caused by delayed receivables, leading DocGo to explore strategic alternatives.
Mobile healthcare service provider DocGo Inc has announced the official launch of a strategic review process aimed at exploring various strategic alternatives to maximize shareholder value.
DocGo Inc., a mobile healthcare service provider, has announced the initiation of a strategic review process. This review will explore various alternatives like business cooperation, capital restructuring, asset sales, and mergers and acquisitions to maximize shareholder value. The company's board aims for systematic assessment to determine the optimal strategic path, emphasizing that no specific timetable has been set but the process will be prudent.
DocGo (NASDAQ:DCGO) Price Target Cut to $2.50 by Analysts at Stifel Nicolaus
Stifel Nicolaus has lowered its price target for DocGo (NASDAQ:DCGO) to $2.50 from $4.00, while maintaining a "buy" rating, indicating a potential upside of 218%. Despite a Q4 revenue beat and raised 2026 revenue guidance of $290M–$310M, the company faces significant execution risk due to a large EPS miss, year-over-year revenue decline, and weak margins, with the stock currently trading around $0.79. DocGo is exploring strategic alternatives to push towards profitability.
DocGo (NASDAQ:DCGO) Given "Buy" Rating at Needham & Company LLC
Needham & Company LLC has reiterated a "Buy" rating for DocGo (NASDAQ:DCGO) with a price target of $3.00, suggesting a potential upside of 361.54%. Despite a mixed analyst outlook that averages to a "Hold" rating, the company recently beat Q4 revenue expectations and provided 2026 revenue guidance between $290M–$310M, though EPS significantly missed estimates. Institutional investors have shown increased interest, with several firms growing their stakes in DocGo.
DocGo Inc. (NASDAQ:DCGO) Q4 2025 Earnings Call Transcript
DocGo Inc. reported Q4 2025 earnings, with revenue of $74.9 million, exceeding expectations, but an adjusted EBITDA loss of $11.6 million, slightly worse due to migrant program wind-down costs. The company increased its 2026 revenue guidance to $290-310 million and adjusted EBITDA loss guidance to $5-10 million, driven by strong performance in its virtual care offering (SteadyMD), improved hiring in medical transportation, and cost efficiency initiatives. DocGo plans to explore strategic alternatives to maximize shareholder value and aims for profitability in the latter half of 2026.
DocGo Inc. (DCGO) Posts Fourth Quarter Loss, Surpasses Revenue Projections
DocGo Inc. (DCGO) reported a significant net loss of $0.53 per share in its fourth quarter, falling short of analyst expectations, yet it surpassed revenue projections with $74.94 million. The company's shares have declined 25.1% year-to-date, and investors are now looking to future earnings guidance and analyst revisions to gauge its stock performance. Despite mixed estimate revisions, DocGo currently holds a Zacks Rank #3 (Hold).
DocGo Q4 2025 Earnings Call: Financial Results & Forward-Looking Statements - News and Statistics
DocGo Inc. held an earnings conference call to discuss its Q4 2025 financial results. The call included remarks from the CEO and CFO, and an introductory statement cautioned listeners about forward-looking statements, highlighting inherent risks and uncertainties. The article also mentions the use of non-GAAP financial measures, with reconciliations available in their SEC filings.
DocGo Q4 Earnings Call Highlights
DocGo reported Q4 revenue of $74.9 million and an adjusted EBITDA loss of $11.6 million, with revenue exceeding guidance despite the wind-down of migrant programs. The company raised its 2026 revenue guidance to $290 million to $310 million and narrowed its adjusted EBITDA loss outlook, targeting profitability in the second half of 2026 driven by SteadyMD and Remote Patient Monitoring. DocGo has also initiated a process to explore strategic alternatives and took non-cash impairments, ending the year with $68.3 million in cash.
DocGo Inc. (DCGO) Reports Q4 Loss, Beats Revenue Estimates
DocGo Inc. (DCGO) reported a Q4 loss of $0.53 per share, significantly missing the Zacks Consensus Estimate of a $0.1 loss, and down from earnings of $0.04 a year ago. Despite the earnings miss, the company's Q4 2025 revenue of $74.94 million surpassed analyst estimates by 6.14%. The stock has underperformed the market year-to-date, and its near-term outlook, based on estimate revisions, results in a Zacks Rank #3 (Hold).
DOCGO ($DCGO) Releases Q4 2025 Earnings, Stock Rises
DOCGO ($DCGO) released its Q4 2025 earnings, reporting a loss of -$0.53 per share, missing estimates, but revenue of $74.94 million, which beat estimates. Following the announcement, the stock price rose by 8.42%. Insider trading activity shows one sale in the past six months, while institutional holdings saw significant additions and removals by various hedge funds.
[10-K] DocGo Inc. Files Annual Report | DCGO SEC Filing - Form 10-K
DocGo Inc. (DCGO) has filed its annual report on Form 10-K for the fiscal year ended December 31, 2025. The report details the company's financial performance, including a net loss of $196.4 million in 2025 following gains in prior years, and outlines significant impairment charges and a decline in Mobile Health Services revenue due to the wind-down of migrant-related projects. DocGo also faces liquidity concerns and potential delisting from Nasdaq due to its stock price.
DocGo (NASDAQ: DCGO) swings to 2025 loss but raises 2026 outlook
DocGo Inc. reported a significant net loss of $196.4 million in 2025, a swing from a $13.4 million income in 2024, primarily due to the wind-down of migrant-related programs and substantial non-cash impairments. Despite this, the company raised its 2026 revenue guidance to $290–$310 million and expects a narrower adjusted EBITDA loss of $5–$10 million, with profitability anticipated in the second half of 2026 driven by core business growth and efficiency initiatives. DocGo has also initiated a formal process to explore strategic alternatives to maximize shareholder value.
DocGo Announces Fourth Quarter and Full Year 2025 Results
DocGo Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025, showing a significant decline in total revenue due to the wind-down of migrant-related programs, but an increase in core health services. The company has raised its 2026 revenue and Adjusted EBITDA guidance, attributing it to customer expansions, improved EMS hiring, and efficiency initiatives, and also initiated a formal process to explore strategic alternatives to maximize shareholder value. Management believes the company is on track to achieve profitability in the second half of 2026.
Did DocGo Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Halper Sadeh LLC, an investor rights law firm, is investigating potential breaches of fiduciary duties by certain officers and directors of DocGo Inc. (NASDAQ: DCGO). The firm encourages long-term DocGo shareholders to contact them to discuss their legal rights and options, including seeking corporate governance reforms or financial incentives. Halper Sadeh LLC emphasizes that shareholder involvement can improve company policies and enhance shareholder value.
Did DocGo Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Halper Sadeh LLC is investigating whether DocGo Inc. (NASDAQ: DCGO) officers and directors breached their fiduciary duties to shareholders, amid a 4.92% stock decline on the news. The investigation adds a legal layer to the company's stock, which is trading near its 52-week low. Shareholders are encouraged to contact the firm to discuss potential legal actions, including corporate governance reforms or financial recovery.
Did DocGo Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of DocGo Inc. (NASDAQ: DCGO) breached their fiduciary duties to shareholders. The firm encourages long-term shareholders to contact them to discuss legal options, including seeking corporate governance reforms and financial incentives. This investigation aims to enhance transparency and accountability within the company for the benefit of investors.
DocGo Inc. (NASDAQ:DCGO) Given Average Recommendation of "Hold" by Analysts
DocGo Inc. (NASDAQ:DCGO) has received a consensus "Hold" rating from five analysts, with an average 12-month price target of $2.25. The stock opened at $0.67 with a market capitalization of $65.75 million and is trading below its 50- and 200-day moving averages. Institutional investors own 56.44% of the shares, with varied analyst opinions ranging from "sell" to "buy" recommendations.
DocGo Conference: CEO Maps “Healthcare at Any Address” as Company Targets $280M-$300M 2026 Revenue
DocGo (NASDAQ: DCGO) aims for $280M-$300M revenue in 2026 from its core business, excluding past COVID and migrant contracts, and expects to achieve a break-even adjusted EBITDA run rate by year-end after an initial loss. The company emphasizes its mobile health and medical transportation services, leveraging a large operational scale and technological integration with platforms like Epic to provide "healthcare at any address" and reduce unnecessary emergency department usage. DocGo focuses on improving patient access, closing care gaps, and positioning for value-based care, supported by high patient satisfaction and strategic acquisitions like SteadyMD.
DCGO Technical Analysis & Stock Price Forecast
The technical analysis for DocGo Inc (DCGO) indicates a "Strong Sell" consensus based on a combination of moving averages and oscillators. Key indicators like the MACD and several simple moving averages also signal a sell. The stock is currently trading below its 60-day and 200-day moving averages, with immediate resistance at $0.817 and support at $0.654.
DocGo to Announce Fourth Quarter and Full Year 2025 Results on Monday, March 16, 2026
DocGo Inc. (Nasdaq: DCGO) will release its financial results for the fourth quarter and full year ended December 31, 2025, after market close on Monday, March 16, 2026. The company will also host a conference call at 5:00 p.m. ET on the same day to discuss these results and its 2026 outlook. DocGo is a leading provider of technology-enabled medical transportation and mobile health services, aiming to reshape healthcare delivery.
DocGo's Q4 2025: What's Priced In After a Year of Misses?
DocGo (DCGO) has experienced a year of significant earnings misses, with its stock price reflecting a deeply pessimistic market sentiment. Ahead of its Q4 2025 report, analysts forecast an EPS of -$0.14, a figure that has remained unchanged, suggesting that expectations of poor performance are already "priced in." While the loss of migrant-related revenue impacted the overall decline, DocGo's core medical transportation segment continues to grow, and the company generated positive operating cash flow despite a reported net loss, signaling a more complex financial picture than top-line numbers suggest.
DocGo to Announce Fourth Quarter and Full Year 2025 Results on Monday, March 16, 2026
DocGo Inc. (Nasdaq: DCGO) announced it will release its financial results for the fourth quarter and full year ended December 31, 2025, after market close on Monday, March 16, 2026. Management will host a conference call and webcast at 5:00 p.m. ET on the same day to discuss these results and provide an outlook for 2026. Details for accessing the call and webcast are provided for investors.
DCGO Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a comprehensive financial overview of DOCGO INC (DCGO), presenting its income statement, balance sheet, cash flow, and key financial ratios for both annual and quarterly periods. It highlights the company's financial health, noting its strong Piotroski F-Score and cash-backed earnings quality, alongside moderate profitability and revenue growth. The report also addresses frequently asked questions about DCGO's financial performance.
Large DocGo (DCGO) holder Vashovsky gifts shares, trims stake to 0.2%
DocGo Inc. investor Stanley Vashovsky has significantly reduced his stake in the company, now beneficially owning just 0.2% of the common stock. This reduction comes after a series of large stock gifts to estate-planning and charitable trusts between 2022 and February 2026, including 4,914,451 shares to a not-for-profit organization. Vashovsky, who originally acquired over 13.1 million shares through the Ambulnz merger and additional equity awards, is no longer considered a major shareholder, having fallen below the 5% beneficial ownership threshold.
DCGO Technical Analysis & ETF Price Forecast
This article provides a technical analysis and price forecast for DocGo Inc (DCGO), an ETF. It presents a "Strong Sell" overall consensus based on aggregated technical signals, though individual moving averages suggest a "Buy" signal. The analysis also details momentum indicators, support and resistance levels, and various technical indicators, most of which currently show a "Neutral" sentiment due to missing data.
DocGo Named in U.S. News & World Report’s 2024-2025 Best Companies to Work for
DocGo (Nasdaq: DCGO), a leading provider of mobile health services, has been recognized by U.S. News & World Report as one of the 2024-2025 Best Companies to Work For. The company was specifically noted among the Best Companies to Work For – Northeast, highlighting its success in meeting employee needs. This recognition underscores DocGo's commitment to an employee-centric culture, which its CEO believes leads to happier employees and better patient care.
DocGo (DCGO) to Release Quarterly Earnings on Thursday
DocGo (DCGO) is scheduled to release its quarterly earnings report on Thursday. This announcement is pertinent for investors and stakeholders, as earnings reports often influence stock performance and provide insight into a company's financial health and future outlook. The article originates from MarketBeat, a platform that tracks stock market alerts and financial news.
DocGo Announces Upcoming Participation at TD Cowen 46th Annual Health Care Conference
DocGo Inc. (Nasdaq: DCGO) announced that CEO Lee Bienstock will participate in 1x1 meetings and deliver a presentation at the TD Cowen 46th Annual Health Care Conference on Monday, March 2nd, at 9:10 AM ET. A webcast of the presentation will be available on DocGo's investor relations website. DocGo is a leading provider of technology-enabled mobile health services, offering a platform that includes mobile health, remote patient monitoring, ambulance services, and a 50-state virtual care network.
DocGo Inc. (NASDAQ:DCGO) Receives Average Rating of "Hold" from Analysts
DocGo Inc. (NASDAQ:DCGO) has received an average "Hold" rating from seven analysts, with an average 1-year price target of $3.21. The company's stock opened at $0.71, has a market cap of approximately $69.5 million, and is trading with negative earnings. Institutional investors currently own about 56.4% of the stock.
DocGo (NASDAQ:DCGO) Shares Down 6.3% - Here's What Happened
DocGo (NASDAQ:DCGO) shares fell 6.3% on Monday, trading at $0.7286 with significantly lower-than-average volume. The company has a market cap of $71.3 million and reported negative earnings, missing analyst EPS estimates while exceeding revenue expectations in its last quarterly report. Analysts maintain a "Hold" consensus rating with a $3.21 average price target, despite mixed individual ratings.
DocGo receives Nasdaq notice for minimum bid price non-compliance By Investing.com
DocGo (NASDAQ:DCGO) has received a notice from Nasdaq for non-compliance with the minimum bid price rule, as its stock traded below $1.00 for a period. The company has 180 calendar days to regain compliance, which may involve achieving a closing bid price of at least $1.00 for ten consecutive business days or potentially undergoing a reverse stock split. This development comes as the company navigates the winding down of a significant contract and plans to expand its virtual care division.
DocGo receives Nasdaq notice for minimum bid price non-compliance
DocGo Inc. (NASDAQ:DCGO) has received a notice from Nasdaq for non-compliance with the minimum bid price rule, as its stock traded below $1.00 per share for an extended period. The company has 180 days, until July 27, 2026, to regain compliance by having its shares close at $1.00 or more for at least ten consecutive business days. DocGo is exploring options, including a reverse stock split, to address the deficiency and avoid potential delisting.
DocGo Receives Nasdaq Notice Over Minimum Bid Price
DocGo (DCGO) has received a notice from Nasdaq for failing to meet the minimum bid price requirement of $1.00 per share. The company has until July 27, 2026, with a potential extension, to regain compliance or face delisting. An analyst rates DCGO as a Hold with a $0.84 price target.
DocGo Disclosed Failure to Satisfy a Continued Listing Rule or Standard
DocGo (DCGO) received a Nasdaq notice on January 26, 2026, indicating non-compliance with Listing Rule 5550(a)(2) because its common stock's closing bid price fell below $1.00. The company has until July 27, 2026, to regain compliance by maintaining a closing bid of at least $1.00 for ten consecutive business days, with the possibility of an extended period or a reverse stock split. Trading of the stock remains unaffected.
DocGo receives Nasdaq notice for minimum bid price non-compliance
DocGo Inc. announced it received a Nasdaq notice for non-compliance with the minimum bid price rule, as its stock fell below $1.00 per share. The company has 180 days to regain compliance, potentially through a reverse stock split. This news follows recent company updates including exceeding third-quarter earnings expectations, expansion plans for its virtual care division, and an extended share repurchase program.
DocGo’s SteadyMD to expand clinical staff by up to 50% amid GLP-1 demand
DocGo's virtual care division, SteadyMD, is set to increase its clinical staff by up to 50% to meet demand for telehealth services supporting GLP-1 weight loss treatments. This expansion occurs while DocGo's stock (NASDAQ: DCGO) trades near its 52-week low. The company is actively recruiting multi-state licensed clinicians, with onboarding expected to begin soon.
DocGo’s SteadyMD Announces Immediate Expansion of Clinical Workforce to Meet Rising Demand for Branded GLP-1 Weight Loss Care
DocGo's virtual care division, SteadyMD, is expanding its clinical workforce by up to 50% to meet the accelerating demand for GLP-1 weight loss care through telehealth services. This initiative aims to support existing partnerships with top consumer, healthcare, and digital wellness brands, ensuring high-quality, compliant, and scalable virtual care as the market for GLP-1 treatments grows. SteadyMD is prioritizing the hiring of experienced, multi-state licensed clinicians to enhance nationwide care delivery.
DocGo’s SteadyMD to expand clinical staff by up to 50% amid GLP-1 demand
DocGo's virtual care division, SteadyMD, is set to increase its clinical workforce by up to 50% to address the climbing demand for telehealth services supporting GLP-1 weight loss treatments. This expansion comes as DocGo's stock is trading near its 52-week low. The company is actively seeking clinicians with multiple state licenses to ensure nationwide care delivery.
DocGo’s SteadyMD to expand clinical staff by up to 50% amid GLP-1 demand
DocGo's virtual care division, SteadyMD, plans to expand its clinical workforce by up to 50% to meet the rising demand for telehealth services supporting GLP-1 weight loss treatments. This expansion comes as the company's stock is trading near a 52-week low. SteadyMD is prioritizing hiring experienced clinicians with multiple state licenses to support nationwide care delivery.
